Apoptosis is a form of programmed cell death that is regulated by the balance between
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …

Impaired apoptosis plays a central role in cancer development and limits the efficacy of
conventional cytotoxic therapies. Deepening understanding of how opposing factions of the …

Background The combination of ibrutinib and venetoclax has been shown to improve
outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with …

Abstract The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab
Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory …

PURPOSE In previous analyses of the MURANO study, fixed-duration venetoclax plus
rituximab (VenR) resulted in improved progression-free survival (PFS) compared with …

Background Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …

The BCL2 inhibitor venetoclax induces high rates of durable remission in patients with
previously treated chronic lymphocytic leukemia (CLL). However, despite continuous daily …

Proteins of the B-cell lymphoma-2 (BCL-2) family control the intrinsic apoptosis pathway.
The pro-apoptotic BCL-2 proteins BAX and BAK can commit a cell to its programmed death …

Purpose B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-
Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to …

PURPOSE The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by
targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis …